Amicus Therapeutics, Inc. FOLD
At closeApr 27, 2026, 4:00 PM EDT
After hours · Apr 27, 4:00 PM ET
52-week range unavailable
- YTD
- +1.76%
- 1 year
- +97.14%
- Market cap
- 4.55B
- Profit margin
- -1.07%
- YTD return
- +1.76%
- 1-year return
- +97.14%
- Open
- 14.49
- Previous close
- 14.49
- Day's range
- 14.49 – 14.49
- Earnings date
- May 7, 2026
2Y +2.75 (+23.42%)
Key statistics
- Enterprise value
- 4.82B
- PEG ratio
- 8.04
- Price / sales
- 0.00
- Price / book
- 16.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 2
- Return on equity
- -2.30%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy8
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 31, 2026 | 0.04667 | — | — | — |
| Feb 20, 2026 | Dec 31, 2025 | 0.07143 | 0.01 | -0.06 | -86.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.03857 | 0.06 | +0.02 | +55.56% |
| Jul 31, 2025 | Jun 30, 2025 | -0.05 | -0.08 | -0.03 | -60.00% |
| May 1, 2025 | Mar 31, 2025 | 0.01 | -0.07 | -0.08 | -800.00% |
| Feb 19, 2025 | Dec 31, 2024 | 0.02 | 0.09 | +0.07 | +350.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | down | Buy | Hold |
| Dec 29, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Dec 22, 2025 | Citigroup | down | Buy | Neutral |
| Dec 19, 2025 | Needham | down | Buy | Hold |
| Dec 19, 2025 | Cantor Fitzgerald | down | Overweight | Neutral |
| Dec 17, 2025 | Citigroup | init | — | Buy |
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 499
- Website
- amicusrx.com
News
Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks 
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold 
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition 
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) 
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy 
SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD 
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD 
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications 
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD 
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
Your note
Sign in to keep a note on FOLD — it syncs with the Stock Master app.